AstraZeneca Loses Bid to Revive Drug Price Suit on Appeal (1)

AstraZeneca PLC failed to convince a federal appeals court that the Medicare Drug Price Negotiation Program is unconstitutional, dealing another blow to the drug industry’s fight against the Biden-era plan.

The US Court of Appeals for the Third Circuit on Thursday affirmed a lower court’s decision that AstraZeneca couldn’t successfully state a due process violation to challenge the negotiation program when the US government selected its diabetes drug Farxiga for price cuts. The court also ruled that the drugmaker lacks standing to pursue its argument that the program violates the Administrative Procedure Act.

“AstraZeneca’s asserted injury to its ability to ...